Theravance, the biotech engine behind GlaxoSmithKline’s bright future in COPD, is gearing up to split in two next quarter, with one publicly traded company handling its revenue-generating drugs and the other leading the charge on R&D.

…read more

Source: Theravance bets it can innovate without GlaxoSmithKline as spinoff nears